Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 6/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSH | P09668 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9100291 | 0.75 | GPR35 (0.39) | ALDH1A1TDP1HTTTSHRSMN1; SMN2 | |
| SCHEMBL1531229 | 0.75 | ALDH1A1 (0.35) | ALDH1A1TDP1HSD17B10TSHRMAPT | |
| SCHEMBL513103 | 0.75 | S1PR4 (0.40) | ALDH1A1TDP1HTTMAPTPOLB | |
| SCHEMBL27587949 | 0.75 | ALDH1A1 (0.31) | ALDH1A1TDP1HSD17B10HTTMAPT | |
| SCHEMBL6543843 | 0.71 | ALDH1A1 (0.36) | ALDH1A1TDP1HTTSMN1; SMN2MAPT | |
| SCHEMBL6544139 | 0.71 | ALDH1A1 (0.34) | ALDH1A1MAPTLMNA | |
| SCHEMBL7408489 | 0.70 | MAPK1 (0.40) | ALDH1A1TDP1HSD17B10TSHRSMN1; SMN2 | |
| SCHEMBL896595 | 0.68 | — | — | |
| SCHEMBL126630 | 0.68 | — | — | |
| SCHEMBL5259407 | 0.67 | KDM4E (0.47) | ALDH1A1TDP1HSD17B10HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103097391-B | Novel spiroheterocyclic compounds as mGlu5 antagonists | RECORDATI IRELAND LTD | 2015-04-08 | — | — | CN | claimed |
| EP-2590985-B1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD (IE) | 2014-05-14 | — | — | EP | claimed |
| EP-2590985-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2013-05-15 | — | — | EP | claimed |
| CN-103097391-A | Novel spiroheterocyclic compounds as mGlu5 antagonists | RECORDATI IRELAND LTD | 2013-05-08 | — | — | CN | claimed |
| EP-2477981-A1 | HETEROCYCLIC MGLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2012-07-25 | — | — | EP | claimed |
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-02-02 | — | — | US | claimed |
| WO-2012004400-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-01-12 | — | — | WO | claimed |
| EP-2178858-B1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD (IE) | 2011-12-28 | — | — | EP | claimed |
| EP-2393780-A1 | HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2011-12-14 | — | — | EP | claimed |
| US-20100317630-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2010-12-16 | — | — | US | claimed |
| CN-101821256-A | Novel heterocyclic compounds as mGlu5 antagonists | RECORDATI IRELAND LTD | 2010-09-01 | — | — | CN | claimed |
| WO-2010089119-A1 | HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2010-08-12 | — | — | WO | claimed |
| EP-2178858-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2010-04-28 | — | — | EP | claimed |
| WO-2009015897-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2009-02-05 | — | — | WO | claimed |
| CN-103097391-B | Novel spiroheterocyclic compounds as mGlu5 antagonists | RECORDATI IRELAND LTD | 2015-04-08 | — | — | CN | disclosed |
| EP-2590985-B1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD (IE) | 2014-05-14 | — | — | EP | disclosed |
| US-8580962-B2 | Spiroheterocyclic compounds as mGlu5 antagonists | RECORDATI IRELAND LTD. (IT) | 2013-11-12 | — | — | US | disclosed |
| EP-0949242-A1 | AROMATIC AMINE DERIVATIVES HAVING NOS INHIBITORY EFFECT | Chugai Seiyaku Kabushiki Kaisha (JP) | 1999-10-13 | — | — | EP | disclosed |
| CN-1187814-A | (hetero) aryloxy-, -thio-and-aminocrotonates, preparation and use thereof | BASF AG (DE) | 1998-07-15 | — | — | CN | disclosed |
| CN-1161687-A | Phenylacetic acid alkyl esters | BASF AG (DE) | 1997-10-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317630-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | GRM5, GRIK5, HRH2 | ALDH1A1 2176/4885TDP1 2429/4885HSD17B10 2830/4885 |
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | OPRM1, GRM5, OPRD1 | ALDH1A1 2610/4885TDP1 2680/4885HSD17B10 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.